Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
This study is a single-arm, multicenter clinical study to evaluate the efficacy and safety of Cadonilimab in combination with gemcitabine/cisplatin as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma|Immune Checkpoint Inhibitors
DRUG: Cadonilimab|DRUG: Gemcitabine|DRUG: Cisplatin
Objective response rate(ORR), ORR is proportion of patients with complete response(CR) or partial response(PR) assessed by investigators according to RECIST v1.1., Up to approximately 2 years|Incidence and severity of adverse events(AEs), Incidence and severity of AEs is aim to evaluate the safety of Cadonilimab in combination with chemotherapy., Up to approximately 2 years
Progression-free survival (PFS), Progression-free survival (PFS) is defined as the time from the first dose of Cadonilimab until documentation of PD (as per RECIST v1.1) or death due to any cause, whichever occurs first., Up to approximately 2 years|Overall Survival (OS), Overall survival (OS) is defined as the time from the first dose of Cadonilimab until death due to any cause., Up to approximately 2 years|Disease control rate (DCR), DCR is proportion of patients with complete response, partial response or stable disease assessed by investigators according to RECIST v1.1., Up to approximately 2 years
This study is a single-arm, multicenter clinical study to evaluate the efficacy and safety of Cadonilimab in combination with gemcitabine/cisplatin as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.